Serum Erythropoietin in Patients with Chronic Renal Failure in the Predialysis Stage

Gergana V. Todorova, A. Akisheva, Diana I. Pendicheva-Duhlenska, Vasil V. Todorov, Milena Y. Stoimenova, Adelaida Ruseva
{"title":"Serum Erythropoietin in Patients with Chronic Renal Failure in the Predialysis Stage","authors":"Gergana V. Todorova, A. Akisheva, Diana I. Pendicheva-Duhlenska, Vasil V. Todorov, Milena Y. Stoimenova, Adelaida Ruseva","doi":"10.2478/jbcr-2023-0018","DOIUrl":null,"url":null,"abstract":"Summary A prospective study was carried out of serum erythropoietin levels in patients with chronic renal failure/chronic kidney disease in the predialysis period. The study is part of scientific project № 2/2022, financed by Medical University-Pleven. Fifty patients were tested – 22 males and 28 females (average age 63.7±13.0), with average serum creatinine 253±127 mcmol/l and average glomerular filtration rate of 22.6±11.8 ml/min/1,72 m2. The results showed that the serum erythropoietin level varied from 1.86 to 48.50 U/l and was below the borderline in only three patients. There were no significant differences between serum erythropoietin and haemoglobin values in both genders. No differences were found between the average haemoglobin values of patients with different values of serum erythropoietin. Non-significant differences were found in the values of serum erythropoietin in patients with different haemoglobin values. A statistically significant difference between the average value of serum erythropoietin was seen in the group of patients who were not undergoing treatment for anaemia with recombinant erythropoietin (8.5±5.9 U/l) and the groups treated with a dose above 3000 UI/weakly (from 18.6±11.3 to 19.7±8.8 U/l).","PeriodicalId":15099,"journal":{"name":"Journal of Biomedical and Clinical Research","volume":"6 1","pages":"136 - 141"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jbcr-2023-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Summary A prospective study was carried out of serum erythropoietin levels in patients with chronic renal failure/chronic kidney disease in the predialysis period. The study is part of scientific project № 2/2022, financed by Medical University-Pleven. Fifty patients were tested – 22 males and 28 females (average age 63.7±13.0), with average serum creatinine 253±127 mcmol/l and average glomerular filtration rate of 22.6±11.8 ml/min/1,72 m2. The results showed that the serum erythropoietin level varied from 1.86 to 48.50 U/l and was below the borderline in only three patients. There were no significant differences between serum erythropoietin and haemoglobin values in both genders. No differences were found between the average haemoglobin values of patients with different values of serum erythropoietin. Non-significant differences were found in the values of serum erythropoietin in patients with different haemoglobin values. A statistically significant difference between the average value of serum erythropoietin was seen in the group of patients who were not undergoing treatment for anaemia with recombinant erythropoietin (8.5±5.9 U/l) and the groups treated with a dose above 3000 UI/weakly (from 18.6±11.3 to 19.7±8.8 U/l).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
透析前慢性肾衰竭患者血清中的促红细胞生成素
摘要 对慢性肾功能衰竭/慢性肾病患者在透析前的血清促红细胞生成素水平进行了一项前瞻性研究。该研究是第 2/2022 号科学项目的一部分,由普莱芬医科大学资助。接受测试的 50 名患者中,22 名男性,28 名女性(平均年龄为 63.7±13.0),平均血清肌酐为 253±127 mcmol/l,平均肾小球滤过率为 22.6±11.8 ml/min/1,72 m2。结果显示,血清促红细胞生成素水平在 1.86 至 48.50 U/l 之间变化,仅有 3 名患者低于边界线。男女患者的血清促红细胞生成素和血红蛋白值之间没有明显差异。不同血清促红细胞生成素值的患者的平均血红蛋白值之间没有差异。不同血红蛋白值患者的血清促红细胞生成素值差异不显著。未接受重组促红细胞生成素治疗的贫血患者组(8.5±5.9 U/l)与接受 3000 UI/weakly 以上剂量治疗的患者组(从 18.6±11.3 U/l到 19.7±8.8 U/l)的血清促红细胞生成素平均值之间的差异具有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Thromboprophylaxis during pregnancy for prevention of adverse complications in patients with inherited thrombophilia: a literature review Evaluation of Ki-67 index in breast cancer cases with intratumor heterogeneity Impact of the COVID-19 pandemic on the patients’ emotional state in general practice in Bulgaria A study of tumor budding and the factors, affecting interpretability of peritumoral budding, based on endoscopic colorectal biopsies from the left and right sided colorectal carcinoma Design of primers and optimization of PCR conditions for the detection of alternatively spliced isoforms of mouse ChAT mRNA
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1